Table 1. Selected characteristics of 10 travelers and assessment of ESBL-producing Enterobacteraciae*.
| Traveler | Destination | Duration, d | Diarrhea | Pretravel | Posttravel | 30 d posttravel | 6 mo posttravel |
|---|---|---|---|---|---|---|---|
| T1 | Nepal | 30 | N | – | AmpC | OXA-209 | OXA-209 |
| T2 | Nepal | 30 | N | – | AmpC, CTX-M1 | AmpC | – |
| T3 | Nepal | 30 | N | OXA-209 | AmpC, CTX-M1, OXA-209 | OXA-209 | OXA-209 |
| T4 | Nepal | 16 | N | – | AmpC | – | NR |
| T5 | Nepal | 30 | Y | – | AmpC, SHV-12 | AmpC | AmpC, CTX-M-1 |
| T6 | Nepal | 15 | Y | – | AmpC, CTX-M-1 | – | – |
| T7 | Nepal | 18 | N | – | AmpC, CTX-M-1 | NR | NR |
| T8 | Uganda | 14 | N | – | – (AmpC)† | – | – |
| T9 | Nigeria | 60 | Y | – | AmpC | – | – |
| T10 | Nepal | 30 | Y | – | AmpC, CTX-M-1 | – | NR |
*Participants submitted samples pretravel (within 1 week before departure), posttravel (within 1 week after return), 30 days posttravel, and 6 months posttravel. ESBL, extended-spectrum β-lactamase; N, no; NR, no sample received; Y, yes; –, ESBL-negative by culture. †T8 was the only participant who was phenotypically ESBL-negative after travel.